NO924279L - Lyofilisert, monoklonalt antistoffpreparat - Google Patents

Lyofilisert, monoklonalt antistoffpreparat

Info

Publication number
NO924279L
NO924279L NO92924279A NO924279A NO924279L NO 924279 L NO924279 L NO 924279L NO 92924279 A NO92924279 A NO 92924279A NO 924279 A NO924279 A NO 924279A NO 924279 L NO924279 L NO 924279L
Authority
NO
Norway
Prior art keywords
monoclonal antibody
lyophilized
antibody preparation
viruses
bacteria
Prior art date
Application number
NO92924279A
Other languages
English (en)
Norwegian (no)
Other versions
NO924279D0 (no
Inventor
Tamotsu Fukuda
Yukio Shimazaki
Yasuyuki Kuroiwa
Shiro Takagi
Original Assignee
Mitsui Toatsu Chemicals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO924279(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Toatsu Chemicals filed Critical Mitsui Toatsu Chemicals
Publication of NO924279D0 publication Critical patent/NO924279D0/no
Publication of NO924279L publication Critical patent/NO924279L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO92924279A 1991-03-08 1992-11-06 Lyofilisert, monoklonalt antistoffpreparat NO924279L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (en) 1991-03-08 1992-02-28 Lyophilized monoclonal antibody preparation

Publications (2)

Publication Number Publication Date
NO924279D0 NO924279D0 (no) 1992-11-06
NO924279L true NO924279L (no) 1992-11-06

Family

ID=12663510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924279A NO924279L (no) 1991-03-08 1992-11-06 Lyofilisert, monoklonalt antistoffpreparat

Country Status (10)

Country Link
US (1) US5908826A (cg-RX-API-DMAC7.html)
EP (2) EP0841067B1 (cg-RX-API-DMAC7.html)
JP (1) JPH0565233A (cg-RX-API-DMAC7.html)
AU (1) AU645187B2 (cg-RX-API-DMAC7.html)
CA (1) CA2082169A1 (cg-RX-API-DMAC7.html)
DE (2) DE69225757T2 (cg-RX-API-DMAC7.html)
DK (2) DK0841067T3 (cg-RX-API-DMAC7.html)
FI (1) FI924982A0 (cg-RX-API-DMAC7.html)
NO (1) NO924279L (cg-RX-API-DMAC7.html)
WO (1) WO1992015331A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
DK1516628T3 (da) * 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
EP1254666A4 (en) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DE60235013D1 (de) * 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
ES2562912T5 (es) * 2003-10-01 2020-02-18 Kyowa Hakko Kirin Co Ltd Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
WO2005035573A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
MX2009003982A (es) * 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
US10736893B2 (en) 2015-11-06 2020-08-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US20240417445A1 (en) * 2023-06-13 2024-12-19 Grifols Worldwide Operations Limited Method for producing a lyophilized composition comprising polyclonal igm and composition obtained

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
DE3786173T2 (de) * 1986-12-15 1993-12-16 Mitsui Toatsu Chemicals Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten.
EP0303088B1 (en) * 1987-08-10 1992-11-11 Miles Inc. Purified igm
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
CA2049342A1 (en) * 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
EP0841067A1 (en) 1998-05-13
DK0531539T3 (da) 1998-10-12
AU1337592A (en) 1992-10-06
NO924279D0 (no) 1992-11-06
EP0531539B1 (en) 1998-06-03
US5908826A (en) 1999-06-01
FI924982L (fi) 1992-11-04
EP0531539A4 (cg-RX-API-DMAC7.html) 1995-04-05
DE69225757D1 (de) 1998-07-09
CA2082169A1 (en) 1992-09-09
FI924982A7 (fi) 1992-11-04
DK0841067T3 (da) 2002-07-15
DE69225757T2 (de) 1998-12-03
AU645187B2 (en) 1994-01-06
DE69232617D1 (de) 2002-06-27
EP0841067B1 (en) 2002-05-22
EP0531539A1 (en) 1993-03-17
DE69232617T2 (de) 2002-10-31
JPH0565233A (ja) 1993-03-19
WO1992015331A1 (en) 1992-09-17
FI924982A0 (fi) 1992-11-04

Similar Documents

Publication Publication Date Title
NO924279L (no) Lyofilisert, monoklonalt antistoffpreparat
JPS6178730A (ja) 免疫グロブリンの加熱処理方法
DE3876125D1 (de) Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.
NO884840D0 (no) Fremgangsmaate for behandling av underjordiske formasjoner med gelfluider som gir forsinket kryssbinding.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
JO1552B1 (en) New pyridizinamine derivatives
NO962017D0 (no) 5,6-Dihydropyron - derivater som protease-inhibitorer og antivirus-midler
ATE214942T1 (de) Fibrinogen-bildungsprotein
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
NO910209L (no) Fremgangsmaate for fremstilling av rekombinante humane anti-cd18-antistoffer.
RU92016490A (ru) Новые 2-сахаринилметил(арил и арокси)ацетаты, применимые в качестве ингибиторов протеолитических ферментов, их композиции и способ их применения
NO962018L (no) 5,6-dihydropyron-derivater som protease-inhibitorer og antivirus-midler
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
JPH09124507A5 (cg-RX-API-DMAC7.html)
LV10191A (lv) Farmaceitiski lidzekli hepatita B virusa izraisito infekciju un slimibu arstesanai
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
RU95105169A (ru) Способ лечения инфекционных болезней, вызываемых h.pyl opi
NO883603L (no) Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel.
NO874107D0 (no) Nye monoklonale antistoffer mot ifn-omega, fremgangsmaate til fremstilling derav og anvendelse for rensing samt paavisning av ifn-omega.
Bauer THE ANTIGENIC DETERMINANTS OF SEVERAL HUMAN PLASMA PROTEINS: Their Determination from the Investigation of the Cross‐Reactions between Human and Other Mammalian Plasmas
ATE265221T1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
DK105391A (da) Et rent faktor i produkt og fremgangsmaade til fremstilling heraf